Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. We utilize T‑Cells from donors with healthy immune function, with the goal to specifically recognize and target cancerous or diseased cells in patients without affecting normal cells. Our investigational off-the-shelf T‑Cells are intended for rapid delivery from inventory to patients.
Transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence
Our unique platform is to create off-the-shelf, allogeneic T-cell libraries that can be used to select the appropriate cells for a patient's unique immune profile.View Technology
Our robust pipeline features multiple T-cell immunotherapies in clinical and pre-clinical development
T-cell immunotherapy for EBV-associated ultra-rare diseases
FDA breakthrough designation & EMA PRIME for EBV+ PTLD
EBV CD19 CAR T
Off-the-shelf, allogeneic platform clinical proof-of-concept